Furosemide Alone or Unexpectedly With Solution of Hypertonic Saline in Nephrotic Syndrome

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The trial will test the hypothesis that hypertonic saline on top of standard diuretic treatment will help achieve adequate diuresis in patients with nephrotic syndrome.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Bialystok
• Treatments: Furosemide

Criteria

Inclusion Criteria:

• 30 consecutive patients with nephrotic syndrome (proteinuria over 3.5 g/day, edema, hypoalbuminemia, dysproteinemia) admitted to II Nephrology Department from November 2018 onwards within 48h of admission,

• age above 18,

• informed consent.

Exclusion Criteria:

• AKI (acute kidney injury) - AKIN criteria level 3,

• CKD (chronic kidney disease) stage 4 and 5 according to KDIGO (Kidney Disease:

Improving Global Outcomes),

• concomittant heart failure NYHA (New York Heart Association) class III or worse,

• active liver disease and liver failure,

• terminal neoplastic disease,

• serum sodium above 145 mmol/l,

• pregnancy.